The European Medicines Agency’s Committee for Veterinary Medicinal Products (CVMP) has recommended granting a marketing authorisation for Scovella (velagliflozin), marking the first positive recommendation for a veterinary medicinal product under the European Union’s limited market regulatory framework established by Regulation (EU) 2019/6. The positive opinion was adopted on 5 November 2026 following a re-examination of the Committee’s negative opinion issued in June. The applicant is Boehringer Ingelheim Vetmedica GmbH. Indication and therapeutic use Scovella is a 15 mg/ml oral solution intended for non-food-producing horses. According to the EMA, it is intended...